Homepage
Medication Guide
What Are the Procurement Channels for Sabril?
Sabril (vigabatrin) is a medication indicated for the treatment of refractory complex partial seizures and infantile spasms. Due to its unique risk-benefit ratio, extreme caution must be exercised dur...
515
Tuesday, January 13th, 2026, 13:09
Recommended Dosage of Bedaquiline
Bedaquiline is a diarylquinoline antimycobacterial agent indicated for use in combination therapy for pulmonary tuberculosis caused by Mycobacterium tuberculosis resistant to at least rifampicin and i...
525
Tuesday, January 13th, 2026, 13:03
What Are the Indications for Bedaquiline?
Bedaquiline is an innovative diarylquinoline anti-mycobacterial drug. It was first approved for marketing in the United States in 2012, offering a new treatment option for drug-resistant tuberculosis....
511
Monday, January 12th, 2026, 13:45
What Are the Purchase Channels for Bedaquiline?
Bedaquiline is the world's first diarylquinoline anti-mycobacterial drug, specifically indicated for the treatment of adult and pediatric (aged 2 years and older with a body weight ≥ 8 kg) patient...
514
Monday, January 12th, 2026, 10:12
Side Effects of Mavacamten (Camzyos)
Mavacamten (Camzyos) is a medication indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). As a drug with a unique mechanism of action, mavacamt...
536
Monday, January 12th, 2026, 10:02
What Are the Precautions for Mavacamten (Camzyos) Administration?
Mavacamten (Camzyos) is an innovative drug indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, and it belongs to the class of cardiac myosin inhibitors. As a prescripti...
539
Monday, January 12th, 2026, 09:53
Dosage and Administration of Camzyos (Mavacamten)
Camzyos (Mavacamten) is a cardiac myosin inhibitor approved in the United States in 2022. It is indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (...
535
Monday, January 12th, 2026, 09:48
What Are the Indications for Mavacamten (Camzyos)?
Mavacamten (Camzyos) is an oral cardiac myosin inhibitor that received its first approval in the United States in 2022. As an innovative therapy, it offers a new treatment direction for patients with ...
509
Friday, January 9th, 2026, 10:33
What Are the Purchase Channels for Mavacamten (Camzyos)?
Mavacamten (Camzyos) is the world’s first approved cardiac myosin inhibitor for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM), and its standardized use is directly relate...
506
Friday, January 9th, 2026, 10:30
Adverse Reactions of Trametinib (Mekinist)
Trametinib (Mekinist) is a targeted therapy drug that demonstrates significant efficacy in the treatment of BRAFV600E or V600K mutation-positive melanoma, but the associated adverse reactions require ...
520
Friday, January 9th, 2026, 10:22
31 / 221
2204 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved